Navigation Links
Sangui BioTech Files Three 2007 Quarterly Reports, Sales Increased, Losses Continue
Date:6/20/2008

WITTEN, Germany, June 20 /PRNewswire-FirstCall/ -- Sangui BioTech International, Inc., has now filed its quarterly reports on Form 10QSB with the SEC covering the quarters ended September 30, 2006; December 31, 2006, and March 31, 2007. In the first nine month of its 2007 financial year the company generated sales of approximately USD 345,000 as compared to approximately USD 95,000 in the first nine months of FY 2006. Operating expenses amounted to almost USD 600,000. The increase as compared to the USD 356,000 in the previous year period is due to increased efforts to expand operations to international markets. The company incurred a net loss of approximately USD 486,000. Sangui used cash in operating acitivities of approximately USD 457,000 (2006 period: approximately USD 242,000). The company's accumulated deficit amounted to USD 22.3 million as of March 31, 2007.

Apart from the contribution margin generated from sales of its cosmetics and wound management products, operations in the first nine months of FY 2007 were financed by investments from several European investors in the amount of approximately USD 543,000. In accordance with US-GAAP the amount is shown as Foreign currency translation adjustments in the profit-and-loss statement and as Effect of exchange rate changes in the cash-flow statement respectively.

In the first nine months of its financial year 2008 (July 1, 2007 through March 31, 2008), Sangui BioTech International, Inc., generated hardly any sales. The company invested in identifying and establishing new sales opportunities in international markets, to wit Mexico and the Arab countries, as well as in the approval process of its Hemospray wound spray in accordance with European, Mexican and US regulations. Ensuing losses were financed by continued investments from several European investors.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. (http://www.pinksheets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49(160)741-27-17

Fax: +49(2302)915-191

e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui BioTech International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Biotech Finishes on a High in August, Burrill Report Says
3. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
4. Spectrum Pharmaceuticals to Present at the Biotechnology Industry Organization Investor Forum
5. Biotech delists shares from TSXV, continues OTCBB trading
6. Frutarom Gewurzmuller and Blessing Biotech Acquisition Conference Call Scheduled for Monday, October 15, 2007
7. MichBio Announces Formation of Biotechnology Legislative Caucus
8. Oncolytics Biotech Inc. announces approval for UK clinical trial
9. Not just humans benefit from animal biotechnology
10. Biotech adds Central American markets to Sucanon distribution
11. GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Fire ... to provide one resource, from start to finish, for Life Safety compliance. ... of Condition surveys requested by the Joint Commission, and fire stopping reviews, inspections, ...
(Date:5/24/2016)... ... May 24, 2016 , ... United Benefit ... welcome new Partner Firm Austin & Co., Inc. Headquartered in Albany, New ... benefits, HR consulting, benefits technology, and beyond. As an employee-owned company celebrating ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... How to ... · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the ... that human error will ever be totally eliminated, many human performance problems can be ...
(Date:5/24/2016)... Irvine, CA — , ... ... the appointment of three new members of its Advisory Board. ... Chico and Sarah Kusch. “All three of them embody the mission ... team. We are very fortunate to have them as we continue ...
(Date:5/24/2016)... ... 24, 2016 , ... Backed by decades of experience, Metroloji ... ensuring the best suited solution to meet regulatory requirements. Their professional staff also ... in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 ... 2016"market research report that provides an overview on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:5/24/2016)... , May 24, 2016  Diana Russell suffers ... her organs from the inside out.  This disease has ... dependent on her children and grandchildren to leave her ... wheelchair, Diana,s family cannot haul the wheelchair.  So if ... the car, and Diana is left to wait for ...
(Date:5/24/2016)... KONG , May 24, 2016 ... , the world , s first ... AV fistula intervention   OrbusNeich, a global ... has expanded its portfolio to include products to treat ... are the company,s first entry devices for lower limb ...
Breaking Medicine Technology: